HIV-infection Clinical Trial
Official title:
Phase I, Drug-drug Interaction Study in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of VM-1500 When Administered Orally, in Combination With Raltegravir or Darunavir
A randomized single dose, drug-drug interaction study in healthy volunteers for VM - 1500 given alone or in combination with Raltegravir or Darunavir in a 3 arm approach. The parallel design is used due to the long half life for VM-1500.
This drug-drug interaction study will not be done as a cross-over study due to the extreme
long half life of the drug. The 24 healthy subjects participating will be randomized to
VM-1500 alone or VM-1500 in combination with Raltegravir or Darunavir in parallel arms.
For the cohort taking VM-1500 40 mg only just 4 subject will be enrolled as 6 subjects have
been already on the same regimen in the trial before. Based on the parallel design it seems
appropriate not to expose more healthy subjects than necessary. This means the available data
of 6 subjects dosed with 40 mg VM-1500 alone will be matched.
Three groups of healthy subjects will be randomized to VM-1500 alone or VM-1500 in
combination with Raltegravir or Darunavir (4:10:10). The healthy subjects will stay at the
unit and receive 40 mg VM-1500 alone or VM1500 in combination with Raltegravir or Darunavir
one time and PK blood samples at several time points will be collected. PK (trough level)
blood samples will also be collected at visits on Days 2, 4,7, 14, 21, and on Day 36.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02291081 -
A Prospective Observational Trial to Determine Cardiovascular Diseases in HIV-infected Patients
|
||
| Completed |
NCT01187719 -
The Effect of Phenytoin on the Pharmacokinetics of Nevirapine and the Development of Nevirapine Resistance
|
Phase 2 | |
| Completed |
NCT02413645 -
A Phase I, Open Label Dose Escalation Study to Evaluate Safety of iHIVARNA-01 in Chronically HIV-infected Patients Under Stable Combined Antiretroviral Therapy
|
Phase 1 | |
| Completed |
NCT02486133 -
Dual Therapy With Boosted Darunavir + Dolutegravir
|
Phase 3 | |
| Completed |
NCT02489435 -
Clinical Trial of Safety and Pharmacokinetics of VM-1500 After Multiple Oral Administration in Healthy Volunteers
|
Phase 1 | |
| Recruiting |
NCT01397669 -
Characteristics of Immunity in Gut Mucosa, Spinal Fluid, Lymph Node and Blood of HIV Negative Thais and Thais With HIV Infection
|
N/A | |
| Completed |
NCT01407237 -
Physiologic Investigation of the Renin Angiotensin Aldosterone Axis in HIV
|
N/A | |
| Completed |
NCT01606722 -
Darunavir Levels, Virological Efficacy, Proviral ADN and Resistances in Patients on Darunavir/Ritonavir Monotherapy
|
N/A | |
| Active, not recruiting |
NCT02411071 -
Clinical Implications of HIV Low-level Viremia at Times of Highly Active Antiretroviral Treatment Regimens
|
N/A | |
| Completed |
NCT01417949 -
Immediate Versus Deferred Antiretroviral Therapy in HIV-infected Patients Presenting With Acute AIDS-defining Events
|
Phase 4 |